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INTRODUCTION
Although in the past three decades we welcomed the
advent of targeted therapies in several cancers,
nelarabine, a purine nucleoside antimetabolite, re-
mains the most recently approved drug to treat re-
lapsed/refractory (R/R) T-cell acute lymphoblastic
leukemia (T-ALL).1,2 Patients with R/R T-ALL experi-
ence a dramatic outcome, a situation that is more
discouraging for the high-risk early T-cell precursor
(ETP) ALL subtype.3 Historically, ETP ALL is associ-
ated with a worse prognosis in children and young
adults compared with other T-ALL subtypes because
of early resistance to chemotherapy.4-6 Although recent
data suggest that allogeneic stem-cell transplantation
in the first complete remission7may overcome the poor
prognosis associated with ETP ALL, novel biologic-
based therapies are needed to improve the outcome
in these patients. A strategy to overcome the current
therapeutic limitations in rare leukemias may involve
the development of functional precision medicine
approaches on the basis of information by drug re-
sponse profiling (DRP) of leukemia cells.8
CASE REPORT
Here we report our experience with a salvage treat-
ment regimen that we designed on the basis of re-
current DRP patterns. We used a selection of 85 drugs
in three patients with R/R ETP/near-ETP ALL after
several lines of chemotherapy (Fig 1A).
Patient 1
A female patient (UPR1) presented at the hematology
and bone marrow transplantation unit of the University
of Parma at the age of 26 years with severe bone pain,
fatigue, and dry cough unresponsive to over-the-
counter analgesics. A WBC count revealed leukocy-
tosis (51,430/cmm), anemia (Hb 9.9 g/dL), and
thrombocytopenia (platelets 95,000/cmm). A chest
computed tomography scan coupled with an 18F-labeled
fluorodeoxyglucose–positron emission tomography scan
identified a metabolically active lymphadenomegaly
in themediastinum. Flow cytometric analysis identified
a bone marrow (BM) blast population (Fig 1A) that was
negative for terminal deoxynucleotidyl transferase,
CD2, CD4, CD8, and CD1a and positive for human
leukocyte antigen (HLA-DR), CD38, CD117, CD33,
CD34, CD56, CD99, cyCD3, CD5, CD7, CD10, CD19,
and CD13.
Because of a T-ALL immature phenotype9,10 and
a myeloid interface, and despite CD5 expression, this
patient was diagnosed with near-ETP ALL.11 Molecular
cytogenetic studies showed the presence of DDX3X-
MLLT10 fusion gene derived from a three-way t(X;3;
10)(p11;?;p13) translocation. Sanger sequencing
detected NOTCH1 and NRAS gain-of-function muta-
tions (Fig 1A). The patient was treated with induction
chemotherapy per the HyperCVAD protocol12,13 with-
out response and reinduced per the GIMEMA LAL0904
regimen (ClinicalTrials.gov identifier: NCT00458848).
A repeated CT scan and marrow examination 2 weeks
after salvage chemotherapy showed persistent bulky
disease and BM infiltration (47% of leukemic blasts).
Patient 2
A female patient (UPR2) presented at the hematology
and BMT unit of the University of Parma at the age of
78 years with relapsed ETP ALL diagnosed 1 year
before (Fig 1A). A WBC count showed leucopenia
(1,380/cmm) with severe neutropenia, anemia (Hb
10 g/dL), and normal platelets (257,000/cmm). Molec-
ular cytogenetic studies revealed an abnormal karyotype
characterized by an isolated numerical abnormality (ie,
47,XX,+4[6]/46XX[4]), a rearrangement of BCL11B,
and an internal tandem duplication of FLT3 (Fig 1A).
Because of advanced age and comorbidities, the
patient was treated with prednisone 0.5 mg/kg and
vincristine 1.4 mg/m2 (days 1, 8, 15, and 22), without
achieving hematologic remission. A cycle of nelar-
abine therapy at the reduced schedule of 750 mg/m2
on days 1, 3, and 5 was administered, which led to a
hematologic improvement for 1 year, when she pre-
sented at our hospital with neutropenia (neutrophils
840/cmm) and anemia (Hb 10 g/dL), with a re-
expansion of the leukemic clone.
Patient 3
A male patient (UPG3) presented at the hematol-



















































































































































































































































































































































RBC 4010 3170 4720 ×10^6 / uL
Hb 13.5 9.8 9.7 g/dL
MCV 99 91 103 fL
WBC 5030 3750 4720 ×10^3 / uL
N 3280 2720 3870 ×10^3 / uL
L 1280 540 425 ×10^3 / uL
PLT 170 210 110 ×10^3 / uL
UPG3UPR2
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leucopenia (WBC 2,200/cmm), anemia (Hb 11 g/dL), and
a moderate thrombocytopenia (platelets 115,000/cmm).
Morphologic and flow cytometric analysis of BM cells
(Fig 1A) showed a diffuse infiltration of lymphoid blasts
negative for CD3, CD2, CD1a, CD8, CD4, CD33, CD117,
CD56, and CD10 and positive for CD7, CD38, CD99, cCD3,
deoxynucleotidyl transferase, CD34, CD13, CD5 (45%),
and HLA-DR, consistent with a diagnosis of ETP ALL.10
Cytogenetics showed a normal diploid karyotype. Fluo-
rescence in situ hybridization uncovered a cryptic deletion
of the short arm of chromosome 12 involving ETV6 and
CDKN1B (Fig 1A). A CT/positron emission tomography
scan showed metabolically active cells in the liver, spleen,
and lymph nodes. The patient was treated with induction
chemotherapy per the HyperCVAD protocol,12,13 which led
to complete hematologic remission. Two months after the
second HyperCVAD cycle, the disease relapsed and the
patient was treated with chemotherapy per the Northern
Italy Leukemia Group ALL 10/07 trial.14 A repeated marrow
examination after 2 months showed persistent ETP ALL,
and the patient was further treated with an anti-CD52
monoclonal antibody12 for a cumulative dose of 100 mg,
without benefit.
Because these cases were refractory to repeated standard
induction therapy (UPR1, UPG3), or to salvage regi-
men (UPR2), we decided to support functional precision
medicine approaches to repurpose available therapeutic
agents. Scoring the response in relation to data for T-ALL on
a DRP platform,8 the B-cell lymphoma 2 (BCL2) inhibitor
BH-3 mimetic venetoclax (ABT-199) and the proteasome
inhibitor bortezomib ranked in all three cases among the
most active drugs (Fig 1B). Next, we validated the activity of
venetoclax and bortezomib using an open microwell
microfluidic platform developed by CellPly15 (Bologna, Italy;
Figs 1C and 1D) and an ATP-based cellular viability assay
(Fig 1E) on ETP cells that, consistent with data reported in
the literature,16,17 express a high level of BCL2 (Fig 1AF).
On the basis of these findings, individualized treatment with
venetoclax and bortezomib (VEBO) was then administered
on an outpatient basis, sequentially or in combination, as
off-label agents after approval by the relevant institutional
review board. All patients received a cycle with venetoclax
(800 mg per day × 28 days) by mouth and bortezomib
(1.3 mg/m2 twice a week × 2 [UPR1, UPR2] or × 4
[UPG3]), with no evidence of major toxicities. UPR1 and
UPR2 received antiviral prophylaxis with acyclovir, whereas
UPG3 received antimycotic treatment with micafungin.
Patients obtained a hematologic complete (UPR2) or partial
remission (UPR1 and UPG3) assessed a month after VEBO
initial treatment quantified by morphology, flow cytometry
analysis, and fluorescence in situ hybridization on bone
marrow cells (Figs 1G and 1H). Age-eligible patients (UPR1
FIG 1. (A) Demographic, clinical, and genomic characteristics of the patients at baseline. Cytogenetic studies include karyotyping, fluorescence in situ
hybridization (FISH), and single-nucleotide polymorphism array (question mark indicates undefined chromosome band). Sanger sequencing:
NOTCH1, FBXW7, PTEN, FLT3, N/K/H/RAS, and BRAF hot-spot mutations. Immunophenotyping: +/− indicates 40% to 55% positive bone marrow
(BM). (B) Identification of active molecules in patients with early T-cell precursor (ETP) acute lymphoblastic leukemia (ALL). ETP leukemia cells were
profiled ex vivo with 85 small molecules. Dose-response curves were generated as previously published using five-point drug dilutions in duplicate.8 A
ranked list of top hits was generated according to the criteria, Emax (ie, the % viability at the maximal drug concentration used) of less than 15% and
significant (P, .05) difference of half maximal inhibitory concentration (IC50) value for each drug compared with the median IC50 for each particular
drug in the reference data set.8 In bold: venetoclax and bortezomib (VEBO). (C) Effect of 24 hours of the vehicle (dimethyl sulfoxide), 10 mM hydrogen
peroxide (H2O2), venetoclax, and bortezomib on cellular viability as measured by a functional profiling, on the basis of laboratory-on-a-chip technology,
which allows testing the response of live tumor cells exposed to anticancer drugs in an automated process developed by CellPly. ETP ALL cells (eg,
patient 2 [UPR2]) were labeled with a 7-amino-4-chloromethylcoumarin (CMAC) dye (blue), an anti–human antigen leukocyte (HLA-DR; green), and an
anti-CD34 antibody (yellow) for leukemia cell identification. High-content time-lapsed imaging was performed for 24 hours, every 12 hours, on cells in
480 microwells (75 µm diameter) at a 1 px-1 µm resolution at each time point/condition tested. Cell death was quantified by imaging HLA-DR+/CD34+
cells positive to the propidium iodide (PI) staining (red). Results are expressed as the percentage of PI+/HLA-DR+/CD34+ positive cells relative to the
negative population. (D) Results of C are depicted in the histograms. (E) Effect of venetoclax or bortezomib on cell viability after 72 hours of treatments in
available ETP ALL cells as assesses by an ATP-based luminescence viability assay. Error bars denote 6 standard deviation (SD) of two replicates. (F)
Expression of BCL2 in ETP ALL and non-ETP ALL (11 cases) as assessed by quantitative real-time polymerase chain reaction. Error bars indicate the
mean6 SD of three replicates. Data were analyzed using the ∆∆CT method. (G) BM cytology at relapse (pre VEBO) and after completion of treatment
with VEBO (post VEBO; May-Grünwald Giemsa staining at 63×). The marrow contains 50% (patient 1 [UPR1]), 90% (patient 2 [UPR2]), and 28%
(patient 3 [UPG3]) of lymphoid blasts before treatment, which decreased rapidly after VEBO. A 500-cell count was performed based on examination of
multiple fields to assess hematologic remission (complete remission indicates a blast percentage , 5% in the BM). (H) Antileukemia effect of VEBO
treatment assessed by flow cytometry. CD45+ staining of primary ETP ALL cells at relapse and after one cycle of VEBO. Aminimum of 20,000 events was
collected for each condition. (I) Percentage of DDX3X-MLLT10 (UPR1) and ETV6/CDKN1Bdel (UPG3) FISH-positive BM cells during VEBO treatment
and after an allogeneic hematopoietic stem-cell transplantation. The analysis was performed on 500 to 1,000 interphase nuclei for each experiment; the
cutoff for DDX3X-MLLT10 fusion was 2% and for ETV6/CDKN1Bdel was 3%. UPR2 discontinued her BM follow-up after VEBO and retired to a hospice.
(J) CBC count on the day of the last hematologic work-up. Days indicate the time elapsed from the last treatment (UPR1 and UPG3 from hematopoietic
stem cell transplantation [HSCT], UPR2 from VEBO). BF, bright field; del, deletion; DRP, drug response profiling; Hb, hemoglobin; hyperCVAD,
hyperfractionated cyclophosphamide, vincristine, doxorubicin, dexamethasone, and high-dose methotrexate and cytarabine; L, lymphocytes; MCV;
mean corpuscular volume; N, neutrophils; NILG, Northern Italy Leukemia Group; PLT, platelets; R/R, relapsed/refractory; SSC-A, side scatter.
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and UPG3) underwent an allogeneic stem-cell trans-
plantation, achieving a stable cytogenetic remission (follow-
up . 8 months; Fig 1J). All patients are off therapy and
alive, with a progressive hematologic recovery (Fig 1I).
CONCLUSION
Although current chemotherapy regimens result in com-
plete remission in 80% of adults with T-ALL, patients who
do not achieve a complete remission or who have a primary
resistant disease, including patients with ETP ALL, expe-
rience a dramatic poor prognosis.3,18 To this end, several
groups seek to identify molecularly informed actionable
targets19 or to develop therapeutic strategies to overcome
chemotherapy resistance in T-ALL.20 One approach is to
develop small molecules on the basis of the identification of
tumor dependencies conferred by specific genotypes. This
is, for example, the case of γ-secretase inhibitors inNOTCH1-
mutated T-ALL.21
An alternative option is to develop individualized ap-
proaches on the basis of pattern of responses to small
molecule inhibitors.22 A first example was the development
of a DRP in primary acute myeloid leukemia samples. The
ex vivo testing of 187 drugs in 28 consecutive acutemyeloid
leukemia cases22 led to the identification of five major
taxonomic drug-response subtypes with distinct genomic
features. Importantly, therapies on the basis of DRP resulted
in several clinical responses.22 More recently, Frismantas
et al8 extended this idea and reported a proof-of-concept
study by testing 60 drugs in 68 ALL cases. Selected single
compounds and combinations were validated in xenograft
models. This approach provided compelling evidence that
differences in drug response can be pattern clustered in
patient groups of interest and reveals patient-to-patient
variation.8 For example, the authors identified a subset of
patients with T-ALL without ABL1 mutations or fusions
responsive to dasatinib inhibition, suggesting an indirect
mechanism of sensitivity to dasatinib-based therapy.8
Recently, two research groups independently reported that
ETP ALL expresses high levels of BCL2 proteins compared
with non-ETP ALL cases, resulting in enhanced suscepti-
bility to Bcl2 suppression with BH-3 mimetics, such as
ABT-199.16,23 Venetoclax as a single agent has been shown
to alter proliferation in human T-ALL cell lines and in primary
samples, particularly those carrying an ETP phenotype.16,23
However, although venetoclax antitumor activity is prom-
ising, the rapid emergence of resistance may limit the use
of this drug as a single agent.24,25 Thus, the downregulation
of the antiapoptotic proteins BCL-XL or myeloid cell
leukemia-1, which are not targeted by venetoclax, is a ra-
tional strategy. In support of this hypothesis, recent work
demonstrated that bortezomib, a proteasome inhibitor, in-
duces the BH3-only protein NOXA, which can then
downregulate, among other Bcl-2 protein family members,
myeloid cell leukemia-1.17,26 However, VEBO may go beyond
R/R ETP ALL cases. Interestingly Li et al27 demonstrated
that venetoclax acts synergistically with the MCL1-specific
inhibitor S63845 in a broad panel of T-ALL cell lines and in
zebrafish embryos undergoing transplantation with
T-ALL cells. Moreover, venetoclax showed clinical ac-
tivity in patients with T-ALL both in combination with
chemotherapy28 or decitabine,29 suggesting that it may be
safely included in different therapeutic regimens.
In addition, bortezomib has recently emerged as a potential
modulator of the oncogenic T-ALL driver NOTCH1. In fact,
preclinical studies showed that bortezomib suppresses the
expression of Notch and its target genes (HES1, GATA3,
and RUNX3) and synergizes with dexamethasone, leading
to a near-complete remission of T-ALL xenografted tumors
in vivo,30 supporting the rationale of several ongoing clinical
trials (eg, ClinicalTrials.gov identifiers: NCT02518750 and
NCT03643276).
Our results illustrate the potential of functional drug pro-
filing with the identification of an active regimen with less-
toxic bioactive drugs for patients with highly resistant R/R
T-ALL, and the basis for exploration of this principle for
other leukemia subtypes. In conclusion, VEBO represents
an effective and well-tolerated chemotherapy-free strategy
for R/R T-ALL, including ETP especially, as a bridge to
transplantation in fit patients.
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